Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMDFQLZ)

Drug Name

DNL919 Drug Info

Synonyms

TAK-920

Indication

Disease Entry	ICD 11	Status	REF
Alzheimer disease	8A20	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Triggering receptor expressed on monocytes 2 (TREM2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AL002	DMOY8VA	Alzheimer disease	8A20	Phase 2	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Triggering receptor expressed on monocytes 2 (TREM2)	TTQRMSJ	TREM2_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT05450549) A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL919 in Healthy Participants. U.S.National Institutes of Health.
2	Clinical pipeline report, company report or official report of Denali
3	Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer's disease model. J Exp Med. 2020 Sep 7;217(9):e20200785.